XBIO
Get informed when a big investor buys or sells
+ FollowUndervalued by 76.1% based on the discounted cash flow analysis.
| Market cap | $9.12 Million |
|---|---|
| Enterprise Value | $2.65 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.58 |
| Beta | 2.15 |
| Outstanding Shares | 2,294,364 |
| P/E Ratio | -3.34 |
|---|---|
| PEG | -9.56 |
| Price to Sales | 4.25 |
| Price to Book Ratio | 2.13 |
| Enterprise Value to Revenue | 0.81 |
| Enterprise Value to EBIT | -1.02 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
No data